Inc. (NASDAQ: AFFX) and PathGEN Dx Pte. Ltd., a spin-off molecular
diagnostics company founded by researchers from the Genome Institute of
Singapore, today announced they have signed a Powered
by AffymetrixTM (PbA) Program agreement.
Under this PbA agreement, PathGEN Dx will develop an in-vitro
diagnostic kit for comprehensive pathogen detection using their PathGEN®
PathChip and is based on a patented, efficient, and accurate
microarray-based protocol and analysis method. The kit will be comprised
of PathGEN Dx's proprietary reagents, an automated software package, and
a contract manufactured GeneChip® microarray from Affymetrix.
It will detect the presence of more than 70,000 viral and bacterial
genomes from a wide variety of human samples, annotate the genomic
information, and identify co-infecting pathogens.
Dr. Martin Hibberd, PathGEN Dx Co-Founder, said, "This will be the start
of our development plan for a diagnostic microarray that we feel will
ultimately help medical researchers and surveillance investigators
identify the full range of viruses and bacteria in their samples."
"We are very pleased to have PathGEN Dx join the Affymetrix' PbA
Program. This adds significantly to our PbA Program in which we help
partners to develop novel molecular diagnostic tests that will
potentially provide solutions for directing proper treatment for
patients," said Roger Schaller, Sr. Director of Global Business
Development for Clinical Applications at Affymetrix.
"We are very proud that PathGEN Dx, the first spin-off from GIS, has
achieved this collaboration that will significantly advance their reach
to the clinical diagnostics global market. The journey first began in
2004 as a project in GIS, and then funded by Exploit Technologies in
2008 to clinically validate, productize, and develop the business
strategy. This is an exciting next phase in PathGEN DX's entrepreneurial
journey and we look forward to greater success," said Mr. Philip Lim,
CEO of Exploit Technologies, A*STAR's technology transfer arm.
"The Genome Institute of Singapore is pleased to support PathGEN Dx and
look forward to incubating more startups in the future," said Prof. Ng
Huck Hui, Acting Executive Director of GIS.
This PbA Program agreement also provides PathGEN Dx access to
Affymetrix' international distribution network.
Dr. Christopher Wong, Founder of PathGEN Dx, added "We are pleased to
join the ranks of other PbA Program partners, such as Roche Diagnostics
and Pathwork Diagnostics in adopting the Affymetrix technology in our
IVD product development program."
Source: Affymetrix, Inc.